Needham & Company LLC Reaffirms Buy Rating for Taysha Gene Therapies (NASDAQ:TSHA)

Taysha Gene Therapies (NASDAQ:TSHA)‘s stock had its “buy” rating reiterated by investment analysts at Needham & Company LLC in a report released on Thursday,Benzinga reports. They presently have a $6.00 price target on the stock. Needham & Company LLC’s price target would suggest a potential upside of 275.00% from the stock’s current price.

Several other research firms have also weighed in on TSHA. Canaccord Genuity Group lifted their price objective on shares of Taysha Gene Therapies from $6.00 to $8.00 and gave the stock a “buy” rating in a research note on Friday, November 15th. Chardan Capital reissued a “buy” rating and set a $7.00 price objective on shares of Taysha Gene Therapies in a research note on Wednesday. JMP Securities reissued a “market outperform” rating and set a $5.00 price objective on shares of Taysha Gene Therapies in a research note on Tuesday, November 12th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $7.00 price objective on shares of Taysha Gene Therapies in a research note on Tuesday, November 12th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $6.63.

Taysha Gene Therapies Stock Up 0.6 %

Shares of NASDAQ:TSHA opened at $1.60 on Thursday. Taysha Gene Therapies has a one year low of $1.19 and a one year high of $4.32. The company has a 50 day moving average of $1.67 and a 200-day moving average of $1.98. The company has a debt-to-equity ratio of 0.48, a current ratio of 5.51 and a quick ratio of 5.51. The stock has a market cap of $327.91 million, a price-to-earnings ratio of 2.54 and a beta of 0.93.

Taysha Gene Therapies (NASDAQ:TSHA) last issued its quarterly earnings results on Wednesday, February 26th. The company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.01. Taysha Gene Therapies had a negative net margin of 229.67% and a negative return on equity of 106.36%. The company had revenue of $2.02 million during the quarter, compared to analysts’ expectations of $2.05 million. On average, sell-side analysts forecast that Taysha Gene Therapies will post -0.35 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Ground Swell Capital LLC bought a new position in Taysha Gene Therapies in the fourth quarter valued at approximately $25,000. Creative Planning bought a new position in Taysha Gene Therapies in the third quarter valued at approximately $28,000. Cibc World Markets Corp bought a new position in Taysha Gene Therapies in the fourth quarter valued at approximately $28,000. E Fund Management Co. Ltd. bought a new position in Taysha Gene Therapies in the fourth quarter valued at approximately $31,000. Finally, Hsbc Holdings PLC lifted its stake in Taysha Gene Therapies by 65.6% in the fourth quarter. Hsbc Holdings PLC now owns 20,391 shares of the company’s stock valued at $36,000 after buying an additional 8,076 shares in the last quarter. Institutional investors own 77.70% of the company’s stock.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.